Answers are grounded in this paper and cite their sources.
It is time for a Turning Point in KeratoconusKeratoconus (KC) is no longer a rare disease 1 , especially in certain geographical areas it reaches peaks of endemic value.The therapies and innovations of the last years', starting with crosslinking, have drastically changed the prognosis and quality of life of our patients.New combined therapies, minimally invasive refractive enhancement treatments, have changed and are changing history. 2 Increasingly sophisticated diagnoses, intelligent CT scanners, machine learning and artificial intelligence are at the service of ophthalmologists who are passionate about the subject and of patients for higher, refined and early diagnoses. 3his has made keratoconus a subspecialty of modern ophthalmology and poses ever new and exciting challenges in the clinical, diagnostic, and therapeutic fields.There was a need for an international society dedicated to this disease, distinct and separate, but which is open to dialogue with the most important international societies of refractive and anterior segment eye surgery.Thus, the IKS (International Keratoconus Society) was finally born, the home of ophthalmologists who deal with keratoconus and of all those who want to dedicate themselves to this fascinating sector of ophthalmology.Such an important Society could not fail to have an equally important scientific Journal, and we have the honor of having the International Journal of Keratoconus and Ectatic Corneal Diseases (IJKECD) as our official IKS scientific Journal. 3 cannot hide a certain emotion, because it was precisely in this Journal that the M nomogram 4,5 for the standardized treatment of individualized crosslinking of ectatic corneas of all thicknesses was born, as awarded in the ESCRS Congress in 2019 in Paris with the "Joseph Colin Prize" for innovating therapies in the field of Keratoconus. 4,5he "M nomogram" allows safe and effective setting of CXL parameters based on thickness minimum preoperative corneal membrane, also allowing the standardized treatment of thin and ultrathin ectatic corneas with a minimum thickness between 250 and 400 µm, keeping the fluence standardized in the Dresden Protocol constant (5.4 J/cm 2 ). 4,5ctually, the preliminary results on new epithelium-on accelerated CXL protocols with progressively higher fluence and pulsed light show that a new pachymetry-based PFPL M Epi-on ACXL nomogram stabilizes ectasia progression. 6Higher fluence Epi-on ACXL increases CXL penetration, with better functional outcomes in the absence of complications, thus paving the way to a replacement of epithelium-off crosslinking treatments.From a clinical and practical perspective, a safer and faster transepithelial crosslinking treatment with an efficacy profile comparable to Epi-off CXL, with no adverse events and capable of quickly rehabilitating patients with progressive KC to resume their school or work activities, represents a great challenge and a highly interesting goal.The early evidence of my recent studies will allow surgeons to extend the indications for the photodynamic variable fluence ACXL protocol to increasingly younger patients, potentially to treat developmental ectasias even in the pediatric age, before or after intrastromal refractive surgery procedures (LASIK and ReLEx).It may also allow them to perform bilateral treatments when needed, with much-improved patient compliance and clinical workflow, including the possibility of outpatient treatments conducted on the same day to reduce the burden of time and organization for both the patient and the surgeon.Moreover, this treatment protocol can be repeated if the progression of ectasia restarts during the follow-up, and the advantages of Epi-on procedures can still be retained in terms of excellent compliance and the absence of infectious and uncontrolled corneal scarring. 6he Journal of Keratoconus and Ectatic Corneal Diseases has the honor and task of hosting present and future innovations in clinical and surgical research, in keratoconus diagnostics and in everything relating to genetic, hormonal, inflammatory, environmental and biochemical aspects, including new research topic in ocular microbiota. 7,8ll ophthalmologists of good will are invited to contribute with their studies to the success of the IJKECD, owned and managed by Jaypee Brothers Medical Publishers (P) LTD.In recent years we have witnessed and contributed to a revolution in the knowledge of the pathophysiology of keratoconus, of the clinic and of pathophysiological optics, thanks to machines such as Scheimpflug-based and now OCT-based tomography.Furthermore, the biomechanics of the cornea is increasingly closer, especially motion-tracking Brillouin Microscopy, surely it will contribute to many new discoveries and increasingly earlier diagnoses of ectatic diseases.Crosslinking protocols have been optimized to benefit the patient's compliance by reducing the treatment time to 20 minutes without giving up effectiveness. 9,10ctually, beyond crosslinking, there are surgical options that allow us to correct, partially or totally, the induced refractive error.Intracorneal ring segments (ICRS) implantation represents a minimally invasive surgical option that improves visual acuity by modifying the corneal geometry.The success rate after ICRS implantation is high, and most importantly, the overall complication rate is low with new customized design. 2e have witnessed the birth of a new therapy that promises great results, the corneal allogenic intrastromal ring segments consisting of ring segments derived from allogenic eye bank-processed donor corneas that can be combined simultaneously or sequentially with corneal crosslinking (CXL) procedure in keratoconic patients intolerant to rigid gas permeable contact lenses. 2 Selective ray-tracing-guided sequential and simultaneous excimer laser transepithelial photorefractive or phototherapeutic keratectomy combined with conventional and accelerated CXL is another way in selected cases to improve spectacles-corrected distance visual acuity (CDVA) of keratoconic eyes. 5
No takes yet. Share an insight, caveat, or question.
Cosimo Mazzotta (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: